Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada.
Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada.
复制标题
DOI：
10.2807/1560-7917.es.2022.27.38.2200720
复制
发表时间：
2022-09
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
在 COVID-19 大流行期间，流感病毒在加拿大的传播几乎停止，随着 2022 年春季限制的放松，流感病毒又重新出现。加拿大哨兵从业者监测网络采用测试阴性设计，报告 2021/22 年疫苗对 A(H3N2) 流感分支引起的季末疾病的有效性为 36%（95%CI：-38 至 71） 3C.2a1b.2a.2 病毒，被认为在抗原上与 3C.2a1b.2a.1 疫苗株不同。研究结果强化了世界卫生组织将 2022/23 年北半球疫苗更新为更具代表性的 A(H3N2) 分支 3C.2a1b.2a.2 毒株的决定。
Influenza virus circulation virtually ceased in Canada during the COVID-19 pandemic, re-emerging with the relaxation of restrictions in spring 2022. Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network reports 2021/22 vaccine effectiveness of 36% (95% CI: −38 to 71) against late-season illness due to influenza A(H3N2) clade 3C.2a1b.2a.2 viruses, considered antigenically distinct from the 3C.2a1b.2a.1 vaccine strain. Findings reinforce the World Health Organization’s decision to update the 2022/23 northern hemisphere vaccine to a more representative A(H3N2) clade 3C.2a1b.2a.2 strain.